Biocomposites has entered into a multi-year agreement with Zimmer Biomet to exclusively distribute its genex bone graft substitute with its new mixing system and delivery options in the US orthopaedic market.
According to Biocomposites, the genex bone graft substitute is a biphasic composite of exceptional purity that is specifically formulated to balance osteoconductive scaffold strength and persistence in the body to enable the optimal remodelling of bone architecture1.
As part of the new agreement, genex has been upgraded for the US market to include a new closed-mixing system, to shorten preparation time and extend working time. In addition, Biocomposites say that it includes a more comprehensive set of delivery options added to allow a surgeon to inject, mould or prepare beads in accordance with their chosen technique.
Michael Harris, chief executive officer of Biocomposites, commented: “I am delighted we are partnering with Zimmer Biomet to deliver our new genex bone graft substitute product to the US market. Genex is already used and valued by surgeons in over 30 countries, including the US, undertaking 15,000 cases each year. The upgraded offering which we are providing to Zimmer Biomet will further benefit many more physicians and patients across the US.”
Brian Hatcher, president of Zimmer Biomet’s CMFT, foot and ankle and trauma, added: “We are excited to partner with Biocomposites to bring the new genex bone graft substitute kits to surgeons as we continue to advance our mission to alleviate pain and improve the quality of life for people around the world.”
1. Yang HL et al. Bone healing response to a synthetic calcium sulfate/β-tricalcium phosphate graft material in a sheep vertebral body defect model. J Biomed Mater Res B Appl Biomater 2012;100B(7):1911–21.